Toll-like receptors: New targets for multiple myeloma treatment?
Akesolo, Olaia ; Buey, Berta (Universidad de Zaragoza) ; Beltrán-Visiedo, Manuel (Universidad de Zaragoza) ; Giraldos, David (Universidad de Zaragoza) ; Marzo, Isabel (Universidad de Zaragoza) ; Latorre, Eva (Universidad de Zaragoza)
Resumen: Despite recent biomedical improvements in treating multiple myeloma, this disease still remains incurable. Toll-like receptors (TLRs) are key immune receptors that recognize conserved molecular patterns expressed by pathogens and damaged cells. Activation of TLRs can induce several effects including inflammatory responses, modulation of cell cycle, apoptosis, or regulation of cell metabolism. In multiple myeloma there is a dysregulated signalling of TLRs due to an abnormal presence of certain pathogens and release of molecules from damaged cells. Thus, TLRs could be critical players for tumour microenvironment and multiple myeloma progression. This haematological malignancy is characterized by a high percentage of recurrences, where many patients can develop residual drug-resistant malignant cells. Strategic targeting of TLRs might result in novel therapeutic combinations that improve the response to current treatments, reducing relapses. This review examines the potential of TLRs as targets for the treatment of multiple myeloma, making a particular emphasis on their therapeutic applications.
Idioma: Inglés
DOI: 10.1016/j.bcp.2022.114992
Año: 2022
Publicado en: Biochemical Pharmacology 199 (2022), 114992 [12 pp.]
ISSN: 0006-2952
Factor impacto JCR: 5.8 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 39 / 278 = 0.14 (2022) - Q1 - T1
Factor impacto CITESCORE: 9.8 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)
Factor impacto SCIMAGO: 1.329 - Pharmacology (Q1) - Biochemistry (Q1)
Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-20R
Financiación: info:eu-repo/grantAgreement/ES/MECD/FPU17-02586
Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2019-105128RB-I00
Tipo y forma: Article (Published version)
Área (Departamento): Área Fisiología (Dpto. Farmac.Fisiol.y Med.L.F.)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2024-03-18-14:08:48)
Visitas y descargas
Idioma: Inglés
DOI: 10.1016/j.bcp.2022.114992
Año: 2022
Publicado en: Biochemical Pharmacology 199 (2022), 114992 [12 pp.]
ISSN: 0006-2952
Factor impacto JCR: 5.8 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 39 / 278 = 0.14 (2022) - Q1 - T1
Factor impacto CITESCORE: 9.8 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)
Factor impacto SCIMAGO: 1.329 - Pharmacology (Q1) - Biochemistry (Q1)
Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-20R
Financiación: info:eu-repo/grantAgreement/ES/MECD/FPU17-02586
Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2019-105128RB-I00
Tipo y forma: Article (Published version)
Área (Departamento): Área Fisiología (Dpto. Farmac.Fisiol.y Med.L.F.)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2024-03-18-14:08:48)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2022-04-05, last modified 2024-03-19